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2SUMMARY
Objective: To investigate the effect of oral administration of type II collagen (CII ) on
pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis
(AA).
Methods:  Sprague-Dawley rats were fed with bovine CII either before immunization
with Complete Freund’s adjuvant (CFA) or after initiation of arthritis. Hind p aw
secondary swelling was measured and synoviocytes were harvested. Sera from portal
vein of oral tolerized rats were collected and in vitro synoviocytes culture or
synoviocytes-Peyer’s Patches (PP) cells co -culture system were developed.
Interleukin (IL)-1 activity was measured by a mouse thymocyte activation assayed by
MTT dye reduction and tumour necrosis factor (TNF) activity was measured by an
L929 cytotoxicity bioassay. Nitric oxide (NO) and malondialdehyde (MDA) levels
were measured by biochemical me thods.
Results: CII 5, 50 and 500µg/Kg feeding for 7 days before immunization significantly
suppressed hind paw secondary swelling measured at day 16, 20, 24 and 28 (all
P<0.001) and pro-inflammatory mediator (IL-1, TNF, NO and MDA) production by
synoviocytes (all P<0.01) in rats with AA. CII 5, 50 and 500µg/Kg feeding for 7 days
after initiation of arthritis had a similar effect. CII 1, 10, 100 µg/ml had no effect on
IL-1 and TNF production by synoviocytes  in vitro, but CII 10 µg/ml suppressed IL-1
and TNF production by synoviocytes-PP cells co-culture system (P<0.01), which was
antagonized by anti-TGF-β antibody (10 µg/ml) (P<0.01). Portal serum (1:10) from
oral tolerized rats suppressed IL-1 and TNF production by synoviocytes (P<0.01),
which was also antagonized by anti -TGF-βantibody (10 µg/ml) (P<0.01).
Conclusions: Oral administration of CII had prophylactic and therapeutic effects on
AA and over-production of IL-1, TNF, NO and MDA by synoviocytes was
3suppressed.  Bystander active suppression may be the main mechanism of oral CII in
the suppression of synoviocyte function.
4Rheumatoid arthritis (RA) is an autoimmune disease characterized by hyperplasia of
synovium with resultant cartilage destruction. Proliferation of the synovium is
associated with increased production of pro -inflammatory cytokines, mainly
interleukin (IL)-1 and tumour necrosis factor (TNF), which play crucial roles in
cartilage degradation [1,2]. Nitric oxide (NO) and oxygen radials also play an
important role in chondrocyte catabolic activity [3] . Therefore, suppression of
production of these pro-inflammatory mediators by synovial cells may be an
important target of therapy for RA.
Oral tolerance, a state of immunological unresponsiveness induced by oral
administration of antigen, has posed intriguing possibilities for the treatment of
autoimmune diseases including RA, multiple sclerosis and insulin dependent diabetes
[4-8]. Oral tolerance has been applied to prevent and treat autoimmune disease in
several animal models including arthritis. Oral administration of type II collagen (CII)
has been shown to suppress collagen [9-11], adjuvant [12], antigen [13] and pristane
[14] induced arthritis in mice and rats. However, the precise mechanisms of oral
tolerance are not fully known. Studies of experimental autoimmune encephalomyelitis
(EAE) have shown that oral tolerance of myelin basic protein (MBP) was associated
with down-regulation of pro-inflammatory cytokines such as IL-1 and TNF
expressions and up-regulation of suppressive cytokines such as transforming growth
factor (TGF)-βand IL-4 expressions in brain tissue [15]. It is generally agreed that
the regulation of mucosally induced tolerance involves several mechanisms, including
active suppression induced by low doses of antigen and clonal anergy or deletion
induced by high doses of antigen [4 -8,16]. Cells from Peyer’s patches (PP) in the gut -
associated lymphoid tissue (GALT) and TGF -βare reported to mediate the induction
5of active suppression [17,18]. But there are few reports about the mechanisms of
mucosal tolerance to CII in animal models of arthritis [11 -13, 19-22], especially its
effect on synoviocytes.
Adjuvant arthritis (AA) is a commonly used model of human RA with an incidence of
around 90%, which makes it ideal to investigate anti -inflammatory effects.  In the
present study, therefore, we tested the effect of oral administration of CII on pro -
inflammatory mediator production by synoviocytes in rats with AA.
6MATERIALS AND METHODS
Animals Male Sprague-Dawley (SD) rats weighing 150-190 g were obtained from
Animal Centre, Anhui Medical University (China). They were housed five per cage
and fed a standard laboratory chow and water ad libitum. Inbred C57BL/6J mice
weighing 16-20 g were also obtained from this Animal Centre.
Induction and evaluation of AA Complete Freund’s adjuvant (CFA) was prepared
by suspending heat-killed mycobacterium tuberculosis (MT) in liquid paraffin at 10
mg/ml. AA was induced by a single intradermal injection of 100 µl of  CFA into the
left hind paw.  At day 0, 16, 20, 24 and 28 after immunization, the right hind paw
volume was measured with a water replacement plethsmometer (Mukomachi K iai
CD, Japan). Paw swelling (△ml) was calculated by taking away the paw volume at
day 0 from the related one at day 16, 20, 24 and 28.
Oral administration of CII    In the pre-treatment protocol, rats were fed daily doses
of 5, 50 or 500 µg/Kg of bovine CI I (provided by Qilu Pharmaceutical Company,
China) dissolved in 0.01 M acetic acid using an 18 -gauge stainless steel animal-
feeding needle for 7 days prior to immunization. Control rats were only fed the same
volume of vehicle (0.01 M acetic acid). In the treatment protocol, rats were treated
orally with above doses of CII or vehicle for 7 days from day 13 after immunization,
for paw swelling appeared on day 10 -13.
Synovial cell isolation and cultures    Synovial cells (synoviocytes) were isolated as
described [23,24]. After measurement of paw swelling, rats were killed at day 30 after
immunization, and the synovial tissue from right ankle was excised. The synovial
membranes were minced aseptically, then dissociated enzymatically using
collagenase (4.0 mg/ml,  Sigma) in Dulbecco’s modified Eagle’s medium (DMEM,
GIBCO) for 4 h at 37 0C.  After centrifugation for 10 minutes at 500 g, cells were
7resuspended in DMEM with 2 mM L-glutamine, 100 U/ml penicillin, 50 µg/ml
gentamicin, 20 nM HEPES buffer, and 10% fetal ca lf serum (FCS). Cells were culture
in 50 ml culture dishes in humidified 5% CO 2 atmosphere at 37 0C. After adherence
for 18 h, cells were washed thoroughly with phosphate -buffered saline (PBS)
solution. Adherent synovial cells were removed by adding trypsi n-EDTA followed by
washing with PBS containing 2% FCS. Synovial cells collected from different groups
were used in 4-5 passages for subsequent experiments, when they showed
fibroblastoid morphology. They (5×10 5/well) were cultured for 48 h with 5µg/ml
lipopolysaccharide (LPS, Sigma) and the supernatants were collected for
measurement.
Serum collection from oral tolerized rats Rats were treated orally with CII  5, 50 or
500 µg/Kg or vehicle daily for 7 days.  Two days later, blood samples were obtained
from portal vein while rats were under light ether anesthesia. After centrifugation,
pooled serum was added to culture medium of synovial cells, and the dilution of 1:10
was found to be most effective on synoviocyte function.
In vitro experiments   Synovial cells obtained from AA rats were used in 4 -5
passages for subsequent in vitro experiments. They (5×105/well) were cultured for 48
hours in 24-well plates containing DMEM with 10% FCS and 5µg/ml LPS in absence
or presence of CII (1, 10, 100 µg/ml), 1:10 seru m(from non- or tolerized rats) or anti-
TGF-βantibody (R & D Symtems, 10 µg/ml) in humidified 5% CO 2 atmosphere at
37 0C. Supernatants were collected for measurement.
Peyer’s patches (PP) were harvested from normal rats and pooled, minced into single
cell suspensions though nylon mesh in DMEM, and w ashed 3 times. Then PP cells
(106/well) were co-cultured with synovial cells(5×10 5/well) for 48 hours in 24-well
plates containing DMEM with 10% FCS and 5µg/ml LPS in absence or presence of
8CII (10 µg/ml) or anti-TGF-βantibody (10 µg/ml) in humidified 5% C O2 atmosphere
at 37 0C. Supernatants were collected for measurement.
IL-1 activity bioassay   IL-1 activity was measured by a mouse thymocyte activation
assayed by MTT dye reduction [25,26]. The tetrazolium salt 3 -[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT, Sigma) was dissolved in sterile PBS to a
concentration of 5 mg/ml and stored in the dark at 4 0C for up to 1 week. Immediately
before use, stock MTT was filtered (0.22 µm) to remove any formazan precipitate.
Thymocytes (2×106/well) from mice were cultured for 48 hours in 96 -well plates
containing RPMI 1640 medium (GIBCO) supplemented with 5 µg/ml concanvalin A
(ConA, Sigma) and 0.1 ml collected supernatants in triplicate. Three hours before the
termination of culture, cells were pulse d with MTT stock (20 µl/well), returned to 37
0C and incubated for an additional 3h. The plates were centrifuged for 10 min at 1,000
g to pellet cells and MTT formazan product. The supernatant was carefully aspirated
without disturbing the pellet, and form azan was solubilized by addition of isopropanol
(100 µl/200µl supernatant). Insoluble material was then removed by centrifugation for
10 min at 1,000 g. The solubilized formazan in isopropanol was collected and
distributed into 12-well, flat-bottom ELASA plates at a final volume of 100 µl/well.
Plates were read at 570 nm in EL 301 Strip Reader (Bio -Tek, USA) within 1 h of
addition of isopropanol. Values were expressed as mean absorbance (A) of triplicate
wells.
TNF bioassay   TNF activity in the supernatan ts was measured by an L929
cytotoxicity bioassay [27,28].  Briefly, L929 cells (obtained from Department of
Immunology, Beijing University) were cultured in RPMI 1640 medium with 5% FCS
at 105 cells/well for 24 h in 96-well, flat-bottom plates at 37 0C in a 5% CO2
atmosphere. The medium above the non -confluent cell layer was replaced with fresh
9medium containing actinomycin D (4 µg/ml, Sigma) and serial dilutions of
supernatants to be tested for TNF activity. All samples were tested in triplicate. After
a further 24 hour incubation the medium was removed and a 0.5% in 20% methanol
solution of crystal violet was added to the wells.  The absorbance in each well was
assessed with a plate reader at 570 nm.  Cell lysis was calculated as follows: Percent
lysis=(A-B)/A × 100. A is the absorbance of L929 cells cultured only with complete
medium and B is the absorbance of L929 cells cultured with a test samples.
Nitrite estimation Nitrite concentration represented NO level in the supernatant was
measured as described before [29].  Briefly, 100 µl aliquots were removed from
collected supernatants and incubated with an equal volume of Griess reagent (1%
sulphanilamide/0.1% naphthylethylene diamine dihydrochloride/2.5% H 3PO4) at
room temperature for 10 min. The absorban ce at 550 nm was determined in a plate
reader. A standard curve was established with a set of serial dilutions of sodium
nitrite. All samples were assayed in triplicate. Results were expressed as µmol/l.
MDA estimation   Malondialdehyde (MDA) levels represented  lipid peroxidation in
supernatants,  were determined using the method described before [30]. Briefly, MDA
was reacted with thibarbituric acid (TBA) by incubating for 1 h at 95 -100 0C.
Following the reaction, absorbance was measured with a spectroph otometry at 535
nm. Results were expressed as µmol/l.
Statistical analysis   Results were expressed as mean ± SD. Student’s t -test was used




CII oral pre-treatment suppresses AA and synoviocyte function
 To determine if oral administration of CII has prophylactic effect on AA, AA rats
were pre-fed with vehicle or three doses of CII for 7 days before immunization. As
shown in Table 1, AA rats pre -fed with vehicle had significant hind paw secondary
swelling measured at day 16, 20, 24 and 28 after immunization with CFA.  Daily pre -
feeding with CII 5, 50 and 500 µg/Kg significantly suppressed AA at day 16, 20, 24
and 28 after immunization (all P<0.01) w ith the most pronounced effects seen in the
group fed with 50 µg/Kg of CII. The suppression rates ranged between 33.9% and
58.4%.
To investigate the effects of pre -feeding with CII on synoviocyte function in AA rats,
the rats were decapitated at day 30 a fter immunization and IL-1, TNF, NO and MDA
levels produced from synoviocytes were measured. As shown in Table 2, IL -1, TNF,
NO and MDA produced from synoviocytes increased significantly in AA rats as
compared with those in normal rats (all P<0.01).  Daily  pre-feeding of 3 doses of CII
had significant inhibitory effects on IL -1, TNF, NO and MDA production from
synoviocytes as compared with daily pre -feeding with vehicle (all P<0.01) in AA rats.
The most pronounced effect was seen in the group fed with 50  µ g/Kg of CII.
CII oral treatment suppresses AA and synoviocyte function
 To test if oral administration of CII has therapeutical effect on AA, AA rats were fed
with vehicle or three doses of CII for 7 days from day 13 after immunization. As
shown in Table 3, daily oral treatment with CII 5, 50 and 500 µg/Kg also significantly
suppressed hind paw secondary swelling measured at day 20, 24 and 28 after
immunization (all P<0.01).  The suppression rates ranged between 20.2% and 35.8%.
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To examine the effects of oral treatment with CII on synoviocyte function in AA rats,
the rats were decapitated at day 30 after immunization and IL -1, TNF, NO and MDA
produced from synoviocytes were measured. As shown in Table 4, daily feeding of 3
doses of CII had significant inhibitory effects on IL-1, TNF, NO and MDA
production from synoviocytes as compared with daily feeding with vehicle (all
P<0.01) in AA rats. The most pronounced effect was also seen in the group fed with
50  µg/Kg of CII.
CII suppresses synoviocyte functi on via PP cells and TGF-βin vitro
To test if CII has a direct effect on synoviocytes, in vitro experiments were employed.
As shown in Figure 1, CII 1, 10, 100 µg/ml had no effects on IL -1 and TNF
production by synoviocytes of AA rats in vitro.
As CII has been shown to stimulate lymphocyte proliferation in vitro [31, Ding CH et,
al. unpublished data], we investigated if CII acts on synoviocytes via lymphocytes and
TGF-β secreted  by Th3 cells. As shown in Figure 2, CII 10 µg/ml had no effect on
IL-1 and TNF production from synovi ocytes of AA rats in vitro (group 2 vs group 1,
P>0.05). PP cells (106/well) from normal rats also had no effect on IL -1 and TNF
production when co-cultured with synoviocytes (5×10 5/well) from AA rats (group 3
vs group 1, P>0.05). However, CII 10 µg/ml sup pressed IL-1 and TNF production
significantly in the co-culture system (group 4 vs group 2 and 3, P<0.01). Meanwhile,
anti- TGF-βantibody (10 µg/ml) was added and it was demonstrated that anti -TGF-
β, which had no effect on IL-1 and TNF production by synoviocytes(group 5 vs
group 2, P>0.05), significantly antagonised the suppressive effects of CII on IL -1 and
TNF production in the co-culture system (group 6 vs group 4, P<0.01).
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Serum from oral tolerized rats suppresses synoviocyte function in vitro
To determine if the suppressive effects of oral administration of CII on synoviocyte
function are through blood mediators,  we collecte d the portal vein sera from the rats
fed with CII 5, 50 or 500 µg/Kg or vehicle (as a control) daily for 7 days and tested
the effects of these sera on synoviocyte function in vitro.  As shown in Figure 3, as
compared with serum (1:10) from rats fed with v ehicle, serum (1:10) from rats fed
with CII 5, 50 or 500 µg/Kg significantly inhibited IL -1 and TNF production from
synoviocytes of AA rats (all P<0.01).
Furthermore, to test if the inhibitory effects of these sera are via TGF -β in blood, we
added anti- TGF-βantibody (10 µg/ml) together with serum from rats fed with CII
50  µg/Kg or vehicle into the synoviocytes culture medium. As shown in Figure 4,
serum (1:10) from rats fed with CII 50  µg/Kg had inhibitory effects on IL -1 and TNF
production from synoviocytes of AA rats (group 2 vs group 1, P<0.01), which
antagonized by anti-TGF-β(group 4 vs group 2, P<0.01).
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DISCUSSION
Our study demonstrated that oral CII pre -feeding or feeding suppressed secondary
hind paw swelling and pre-inflammatory mediators production in AA. CII had no
direct effect on synoviocyte function in vitro, but it could suppress IL-1 and TNF
production by synoviocytes via TGF -β secrected by PP cells. Furthermore, portal
serum from oral tolerized rats suppressed IL -1 and TNF production by synoviocytes
via TGF-βin vitro.
Beginning with collagen-induced arthritis (CIA) in rats [10] and mice [9], oral
administration of CII has been found to suppress virtually all experimentally inducible
animal models that exist for RA [11 -14, 32]. Histopathological studies showed that
oral administration of CII resulted in reduction of synovial hyperplasia, mononuclear
infiltration, pannus formation, and cartilage erosions [14]. In AA models, using Lewis
rats weighing between 125 to 150 grams, da ily doses of 3 or 30 µg of native chicken
CII abrogated the disease to a statistically significant degree, whereas higher doses or
a dose of 0.3 µg/day were ineffective. Both pre -feeding and feeding suppressed the
disease of AA [12]. In our present study, using 150-190 g SD rats, we found that daily
oral administration of bovine CII 5, 50 and 500 µg/kg for 7 days either before or after
immunization suppressed secondary hind paw swelling of AA. Our results and doses
are consistent with the previous findings [12].  Moreover, we demonstrated, for the
first time, that oral administration of CII either before or after immunization inhibited
the production of pro-inflammatory mediators, i.e., IL-1, TNF, NO and MDA, from
synoviocytes in AA. These results suggest th at suppression of paw swelling by oral
CII may be through suppression of pro -inflammatory mediator production by
synoviocytes. This implies that oral administration of CII could modify the disease
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activity of arthritis, for these pro -inflammatory mediators play crucial roles in
cartilage degradation in inflammatory arthritis [1 -3]. Although the effects of oral
administration of CII in the treatment of RA from clinical trials are inconsistent,
showing no effect, non significant, or significant improvement in  the disease[8, 33-
36], our present study in AA supports the concept that OT induction by CII has a
potential prospect in modifying disease activity of RA.
So far there has not been a convincing explanation why oral administration of CII
suppresses synovial inflammation. In other animal systems a number of studies have
pinpointed the ways by which OT is likely to be achieved [4 -8, 37-39].  It has been
observed in mice and rats that multiple feedings of low doses of a soluble antigen
leads to development of active suppression and regulatory T cells (CD4+ Th2 and
Th3 cells) in GALT containing PP. Th2 cells secrete IL -4 and IL-10, whereas Th3
cells secrete TGF-β. These regulatory T cells migrate to lymphoid organs and target
organs expressing the same antigen . Antigen exposure stimulates cells from these
organs to secrete anti-inflammatory cytokines (TGF-β, IL-4, and IL-10). Multiple
feedings of low doses of a soluble antigen also induced splenic CD4+ CD25+
regulatory cells to produce the anti -inflammatory cytokines [40,41].  These cytokines
downregulate other T-cells responses in the organ in which the autoimmune attack
occurs.  The ability to suppress immune response in the microenvironment in an
antigen non-specific manner is known as bystander suppression [ 4-8, 37-39]. In the
course of bystander suppression induction, PP cells and TGF -βsecreted by Th3 or
CD4+CD25+ cells play important roles. PP cells have been used to transfer tolerance
to soluble antigen [42]. CD4+ and CD8+ regulatory cells were detected in PP as early
as 6 h following oral antigen in TCR transgenic mice [43]. PP -null mice lack
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ovalbumin-specific OT suggests PP cells are required in OT [17]. Similarly, TGF -βis
an important mediator of the active component of OT.  Increased production of this
cytokine has been reported in a number of models of OT and TGF -β-secreting Th3
or CD4+CD25+ T cells can be produced from animals tolerized in this way [4 -8, 40].
Administration of anti-TGF-βantibody in vivo negates the ability of oral MBP to
protect against induction of EAE [18].
The roles of PP cells and TGF-βin OT were verified by our present in vitro study.
We found that CII (1, 10 and 100 µg/ml) had no direct effect on IL-1 and TNF
production by synoviocytes. However, when PP cells were added to the culture
system, CII 10 µg/ml significantly inhibited IL-1 and TNF production by
synoviocytes. This effect of CII was antagonized by anti -TGF-βantibody (10 µg/ml).
Our findings strongly suggest that bystander active suppression is the main
mechanism of OT to CII, which is consistent with previous reports [11-13,19-22]. It
has been reported that spleen cells, and nylon wool -filterer splenic T cells from CII-
induced OT rats adoptively transferred hyporesponsiveness to normal recipients that
were less susceptible to AA or CIA [12, 19], suggesting regulatory T cells mediate the
bystander active suppression.  T cells lines established from CII fed or nasally treated
mice showed increased production of IL -2, IL-10 and TGF-β, and decreased
production of IFN-γ. Meanwhile, TNF-α and IL-6 mRNA expressions in the joint
were diminished by nasal treatment of CII in mice with CIA [11], showing CII
induced mucosal tolerance could suppress local inflammation of joint in CIA.
Neutralization of IL-4 by an anti-IL-4 antibody prevented the suppression of CIA in
mice by oral administration of CII, implying that IL -4 may play a role in its
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suppression [22]. TGF-β1 increased the degree of OT induced by feeding of low -
dose CII in mice and augmented the induction of immunoregulatory CD8 T cells,
which transferred the resistance to CIA induction to normal recipients  [18]. Single
administration of PLGA (a carrier for drug delivery systems) entrapping CII showed a
higher level of TGF-β mRNA expression in PP, but a lower level of TNF -α mRNA
expression in draining lymph nodes in CIA mice [ 44], suggesting TGF-β plays an
important role in OT induction by CII.
Surgical approaches using portacaval shunts showed that the development of OT is
dependent on the hepatic portal circulation [45,46], so we studied the effect of the
serum in portal vein from oral tolerized rats. We found that the serum suppressed IL -1
and TNF production by synoviocytes in vitro, which was antagonized by anti -TGF-
βantibody. This result suggests that TGF-βlevel in the hepatic portal circulation
may also play a role in suppression of synovial inflammation by oral administration of
CII.
In conclusion, oral administration of CII had prophylactic and therapeutic effects on
AA and over-production of IL-1, TNF, NO and MDA by synoviocytes was
suppressed.  CII had no direct effect on synoviocytes, but it could suppress IL -1 and
TNF production by synoviocytes via TGF -β secreted by PP cells in vitro. Portal
vein serum from oral tolerized  rats also suppressed IL-1 and TNF production by
synoviocytes via TGF-β in vitro. Our study suggests that bystander active
suppression may be the main mechanism of OT to CII in the suppression of synovial
inflammation.
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Table 1  Inhibitory effects of oral CII pre-treatment on hind paw swelling in AA
rats
                 Paw Swelling (△ml)Group Dose
µg /kg
        day16        day 20        day 24       day  28
Normal - 0.10±0.02 0.15±0.02 0.20±0.02 0.23±0.02
AA - 0.46±0.09** 0.67±0.12** 0.87±0.14** 1.05±0.12**
CII 5 0.30±0.07††
     (33.9)
0.37±0.07††
     (49.9)
0.42±0.08††
     (51.2)
0.48±0.08††
      (54.1)
50 0.20±0.02††
    (56.1)
0.30±0.04††
     (55.9)
0.36±0.04††
     (58.4)
0.45±0.03††
     (57.5)
500 0.27±0.04††
    (44.3)
0.38±0.03††
    (44.0)
0.45±0.02††
    (47.6)
0.54±0.02††
     (49.0)
SD rats were fed with vehicle (0.01 M acetic acid) or different daily doses of bovine
CII for 7 days prior to immunization. Adjuvant arthritis (AA) was induced by a s ingle
intradermal injection of 100 µl of Complete Freund’s Adjuvant into the left hind paw.
The right hind paw volume was measured with a water replacement plethsmometer at
day 0, 16, 20, 24 and 28 after immunization. Paw swelling (△ml) was calculated by
taking away the paw volume at day 0 from the relevant one at day 16, 20, 24 and 28.
Results are representative of two similar experiments and expressed as mean ± SD,
n=5. **P<0.01 vs Normal group, ††P<0.01 vs AA group. Numbers in parenthesis
represent the inhibitory percentages.
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Normal - 0.44±0.05 28.92±9.81 5.84±1.29 0.63±0.18
AA - 0.67±0.07** 65.54±6.49** 12.14±1.09** 1.86±0.27**
CII 5 0.48±0.05†† 38.46±9.36†† 6.89±1.07†† 0.96±0.34††
50 0.49±0.06†† 32.61±8.86†† 6.46±0.64†† 0.61±0.17††
500 0.53±0.05†† 39.08±10.12†† 6.91±1.39†† 0.72±0.22††
SD rats were fed with vehicle (0.01 M acetic aci d) or different daily doses of bovine
CII for 7 days prior to immunization. Adjuvant arthritis (AA) was induced by a single
intradermal injection of 100 µl of Complete Freund’s Adjuvant into the left hind paw.
At day 30 after immunization, rats were killed  and synoviocytes were isolated and
cultured. IL-1, TNF, NO and MDA secreted from synoviocytes were measured as
described in materials and methods. Results are representative of two similar
experiments and expressed as mean ± SD, n=5. **P<0.01 vs Normal group, ††P<0.01
vs AA group.
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Table 3. Inhibitory effects of oral CII treatment on hind paw swelling in AA rats
                 Paw Swelling (△ml)Group Dose
µg /kg
       day 20        day  24       day  28
Normal - 0.15±0.04 0.23±0.06 0.32±0.07
AA - 0.53±0.07** 0.77±0.03** 0.94±0.07**
CII 5 0.43±0.09††
     (20.2)
0.56±0.04††
     (27.6)
0.65±0.06††
      (30.5)
50 0.37±0.06††
     (30.9)
0.57±0.06††
     (20.6)
0.41±0.08††
     (34.5)
500 0.37±0.05††
    (31.1)
0.49±0.09††
    (35.8)
0.62±0.06††
     (34.2)
Adjuvant arthritis (AA) was induced by a single intradermal injection of 100 µl of
Complete Freund’s Adjuvant into the left hind paw. Vehicle (0.01 M acetic acid) or
different daily doses of bovine CII were fed for 7 days from d 13 after immunization.
The right hind paw volume was measured with a water replacement plethsmometer at
day 0, 20, 24 and 28 after immunization. Paw swelling (△ml) was calculated by
taking away the paw volume at day 0 from the relevant one at day 20, 24 and 28.
Results are representative of two similar experiments and expressed as mean ± SD,
n=5. **P<0.01 vs Normal group, ††P<0.01 vs AA group. Numbers in parenthesis
represent the inhibitory percentages.
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Normal - 0.46±0.06 28.31±9.40 7.25±1.38 0.80±0.24
AA - 0.69±0.04** 64.00±11.39** 13.61±1.56** 2.19±0.32**
CII 5 0.50±0.06†† 47.07±5.92† 8.81±1.24†† 1.02±0.28††
50 0.47±0.05†† 40.31±9.81†† 6.74±0.73†† 0.81±0.17††
500 0.51±0.04†† 49.85±5.17† 7.48±0.68†† 0.93±0.25††
Adjuvant arthritis (AA) was induced by a single intradermal injection of 100 µl of
Complete Freund’s Adjuvant into the left hind paw. Vehicle (0.01 M acetic acid) or
different daily doses of bovine CII were fed for 7 days from day 13 after to
immunization. At day 30 after immunization, ra ts were killed and synoviocytes were
isolated and cultured.  IL-1, TNF, NO and MDA secreted from synoviocytes were
measured as described in materials and methods . Results are representative of two
similar experiments and expressed as mean ± SD, n=5. **P<0.01 vs Normal group,
††P<0.01 vs AA group.
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Figure legends:
Figure 1. Effects of CII on IL-1 and TNF production by synoviocytes of AA rats
in vitro.  Synovial cells (5×105/well) obtained from AA rats on day 30 after
immunization were cultured for 48 hours in 24-well plates containing DMEM with
10% FCS and 5µg/ml LPS in absence or presence of CII (1, 10, 100 µg/ml).
Supernatants were collected for IL-1 and TNF measurement.  Results are expressed as
mean ± SD of  5 independent experiments.
Figure 2. Effects of CII on IL-1 and TNF production by synoviocytes co -cultured
with PP cells in vitro and antagonism of anti-TGF-β antibody.  Peyer’s patches
(PP) were harvested from normal rats and synovial cells were obtained from AA rats
on day 30 after immunization. PP cells (10 6/well) were co-cultured with synovial cells
(5×105/well) for 48 hours in 24-well plates containing DMEM with 10% FCS and
5µg/ml LPS in absence or presence of CII (10 µg/ml) or anti -TGF-βantibody (10
µg/ml). Supernatants were collected for IL -1 and TNF measurement.  ‘+’ represents
‘added’,  ‘-’ represents ‘ not added’. Results are expressed as mean ± SD of  5
independent experiments.  **P<0.01 vs group 2, ##P<0.01 vs group 4.
Figure 3. Effects of serum from oral tolerized rats on IL -1 and TNF production
by synoviocytes of AA rats in vitro.  Sera in portal vein were obtained from rats
treated orally with CII 5, 50 or 500 µg/Kg daily or vehicle for 7 days. Synovial cells
(5×105/well) obtained from AA rats were cultured for 48 hours in 24 -well plates
containing DMEM with 10% FCS and 5µg/ml LPS in absence or presence of the
different serum (1:10). Supernatants wer e collected for IL-1 and TNF measurement.
Results are expressed as mean ± SD of  5 independent experiments.  **P<0.01 vs cells
treated with serum from vehicle -fed rats.
28
Figure 4. Antagonism of anti -TGF-βantibody against the effects of serum from
oral tolerized rats on IL-1 and TNF production by synoviocytes of AA rats in
vitro.  Sera in portal vein were obtained from rats treated orally with CII 50 µg/Kg
daily or vehicle for 7 days. Synovial cells (5×10 5/well) obtained from AA rats were
cultured for 48 hours in 24-well plates containing DMEM with 10% FCS and 5µg/ml
LPS in absence or presence of the different serum (1:10) or anti -TGF-β antibody (10
µg/ml). Supernatants were collected for IL -1 and TNF measurement.  ‘+’ represents
‘added’,  ‘-’ represents ‘ not added’. Results are expressed as mean ± SD of  5
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